These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22689320)

  • 1. Responders to cyclophosphamide: results of a single-centre analysis among systemic sclerosis patients.
    Becker MO; Schohe A; Weinert K; Huscher D; Schneider U; Burmester GR; Riemekasten G
    Ann Rheum Dis; 2012 Dec; 71(12):2061-2. PubMed ID: 22689320
    [No Abstract]   [Full Text] [Related]  

  • 2. [Generalized scleroderma. Treatment with immunosuppressive agents].
    Saporta L; Godeau P; Delrieu F; Delbarre F
    Nouv Presse Med; 1972 Jul; 1(29):1929-30. PubMed ID: 5053601
    [No Abstract]   [Full Text] [Related]  

  • 3. [Survival time of progressive systemic sclerosis patients treated with immunosuppressive drugs].
    Olszewska Z
    Przegl Dermatol; 1989; 76(5-6):430-4. PubMed ID: 2641810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide in scleroderma lung disease.
    Sullivan KM; McSweeney PA; Nash RA
    N Engl J Med; 2006 Sep; 355(11):1173-4; author reply 1174. PubMed ID: 16977701
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclophosphamide in scleroderma lung disease.
    Andreu JL; Silva L
    N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16977700
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclophosphamide in systemic sclerosis: light and shadows.
    Vlachoyiannopoulos PG; Ioannidis JP
    Clin Exp Rheumatol; 2004; 22(5):551-2. PubMed ID: 15485005
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclophosphamide for scleroderma lung disease.
    Martinez FJ; McCune WJ
    N Engl J Med; 2006 Jun; 354(25):2707-9. PubMed ID: 16790705
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclophosphamide in scleroderma lung disease.
    Kuschner WG
    N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16971726
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclophosphamide versus placebo in scleroderma lung disease.
    Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
    N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological reconstitution after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: relationship between clinical benefits and intensity of immunosuppression.
    Bohgaki T; Atsumi T; Bohgaki M; Furusaki A; Kondo M; Sato-Matsumura KC; Abe R; Kataoka H; Horita T; Yasuda S; Amasaki Y; Nishio M; Sawada K; Shimizu H; Koike T
    J Rheumatol; 2009 Jun; 36(6):1240-8. PubMed ID: 19447934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
    Kowal-Bielecka O; Kowal K; Rojewska J; Bodzenta-Lukaszyk A; Siergiejko Z; Sierakowska M; Sierakowski S
    Ann Rheum Dis; 2005 Sep; 64(9):1343-6. PubMed ID: 16100339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.
    Mittal G; Udwadia Z; Joshi VR
    J Rheumatol; 2003 May; 30(5):1121-2; author reply 1122. PubMed ID: 12734923
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of scleroderma].
    Mouthon L
    Rev Prat; 2002 Nov; 52(17):1915-7. PubMed ID: 12532869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mouth opening in patients with systemic sclerosis: base analysis and during follow-up].
    Tanturri De Horatio C; Tirri E; Valletta R; Tirri G; Rengo S
    Minerva Stomatol; 2000 Sep; 49(9):409-13. PubMed ID: 11256201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of scleroderma and dermatomyositis in childhood].
    Ansell BM
    Clin Ter; 1978 Jan; 84(2):123-31. PubMed ID: 648095
    [No Abstract]   [Full Text] [Related]  

  • 17. [Current aspects of immunosuppressive therapy of collagen diseases].
    Marmont A; Rossi F; Bordo D
    Minerva Med; 1973 Jun; 64(46):2436-50. PubMed ID: 4723570
    [No Abstract]   [Full Text] [Related]  

  • 18. Haemopoietic stem-cell transplantation for systemic sclerosis.
    Sullivan KM; Wigley FM; Denton CP; van Laar JM; Furst DE
    Lancet; 2012 Jan; 379(9812):219; author reply 219-20. PubMed ID: 22265628
    [No Abstract]   [Full Text] [Related]  

  • 19. [Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?].
    Verrecchia F; Michel L; Keshtmand H; Wang Y; Launay D; Farge D
    Rev Med Interne; 2009 Nov; 30(11):955-62. PubMed ID: 19349102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic leg ulceration as the presenting feature of diffuse systemic sclerosis in childhood.
    Wahezi DM; Ilowite NT; Kenney-Riley KM; Belamarich PF
    J Pediatr; 2011 Oct; 159(4):698. PubMed ID: 21784448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.